Ipamorelin and CJC-1295: what does 'increases GH' actually buy you?

Both are sold on raising growth hormone, usually together. Ipamorelin works at the ghrelin receptor, CJC-1295 at the GHRH receptor, so the pairing is two different upstream levers on the same output.

Assume they do raise GH. What follows from that?

Less than the marketing implies, and the gap is where all the interesting questions live.

Raising a hormone is not the same as producing the outcome associated with the hormone. GH is released in pulses, and the physiological pattern — amplitude, timing, the overnight profile — appears to matter, not just the area under the curve. A secretagogue that raises total GH while flattening the pattern is not obviously doing the same thing as healthy endogenous secretion.

Then there is what GH is actually for in an adult, which is a narrower question than the anti-ageing framing suggests. Adult growth hormone deficiency is a real diagnosis with real treatment and measurable outcomes. "Somewhat more GH in a person who is not deficient" is a different intervention and the evidence for it being beneficial is not the same evidence.

Ipamorelin's genuine selling point is selectivity — it does not drag cortisol and prolactin up with it the way the older secretagogues did. That is a real advance over GHRP-6 and it is about side effects, not efficacy.

Both safety notes on the ipamorelin page are worth restating because they are mechanistic rather than precautionary.

Glucose. GH opposes insulin. That is basic endocrinology, not a hypothetical, and it means anyone with diabetes or prediabetes is changing a variable they are already managing.

Growth signalling. Anything that increases growth signalling deserves care from anyone with a personal or family history of cancer. Same category of concern as the angiogenesis note on BPC-157 — a mechanism that helps the intended tissue does not check what tissue it is helping.

The glucose one is not theoretical from where I sit. Anything that opposes insulin changes my numbers, and I would find out about it through my CGM before I found out about it through any of the effects people take this for.

Somebody managing diabetes who adds a GH secretagogue without accounting for that is going to have a confusing fortnight.

So the honest summary: it probably does raise GH, the pattern may matter as much as the level, the outcome evidence in non-deficient adults is weak, and there are two specific mechanistic cautions.

And note the reported effect that is most consistent across users is, again, better sleep. Same as epitalon. Same as several others.

At some point "the thing people report is better sleep" stops being a finding about compounds and starts being a finding about self-report.